ReviewWorld journal of stem cells2015
Mesenchymal stem cells as a therapeutic tool to treat sepsis.
Review in World journal of stem cells, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- Antibacterial effects of human mesenchymal stem cells and their derivatives: a systematic review.Frontiers in microbiology · 2024Pooled it
- Protective properties of extracellular vesicles in sepsis models: a systematic review and meta-analysis of preclinical studies.Journal of translational medicine · 2023Pooled it
- Effect of Bone Marrow Mesenchymal Stromal Cell Therapies in Rodent Models of Sepsis: A Meta-Analysis.Frontiers in immunology · 2021Pooled it
- Exploring mesenchymal stem cells as a novel therapeutic approach for HACEK endocarditis: a narrative review.Journal of cardiothoracic surgery · 2026Review
- Non-Viral Therapy in COVID-19: Where Are We Standing? How Our Experience with COVID May Help Us Develop Cell Therapies for Long COVID Patients.Biomedicines · 2025Review
- Mesenchymal stem/stromal cells as a therapeutic for sepsis: a review on where do we stand?Stem cell research & therapy · 2025Review
- Immunomodulatory Functions of Mesenchymal Stem Cells in Tissue Engineering.Archives of Razi Institute · 2025Review
- The antibacterial effect of human adipose-derived stem cells on LL-37-resistant bacteria.PloS one · 2025Article
- The toxic effects of neutrophil extracellular traps on mesenchymal stem cells.Molecular biology reports · 2024Article
- Machine learning reveals the rules governing the efficacy of mesenchymal stromal cells in septic preclinical models.Stem cell research & therapy · 2024Article
- Review
- A Review of the Use of Extracellular Vesicles in the Treatment of Neonatal Diseases: Current State and Problems with Translation to the Clinic.International journal of molecular sciences · 2024Review
- The efficacy of mesenchymal stem cell treatment and colistin-fosfomycin combination on colistin-resistant Acinetobacter baumannii sepsis model.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Article
- Reconditioned monocytes are immunomodulatory and regulate inflammatory environment in sepsis.Scientific reports · 2023Article
- Dose-specific efficacy of adipose-derived mesenchymal stem cells in septic mice.Stem cell research & therapy · 2023Article
- Anti-Inflammatory Effects of Encapsulated Human Mesenchymal Stromal/Stem Cells and a Method to Scale-Up Cell Encapsulation.Biomolecules · 2022Article
- Human Amnion Epithelial Cells and Their Derived Exosomes Alleviate Sepsis-Associated Acute Kidney InjuryFrontiers in medicine · 2022Article
- Immunomodulatory effects of mesenchymal stem cell-conditioned media on lipopolysaccharide of Vibrio cholerae as a vaccine candidate.Stem cell research & therapy · 2021Article
- Therapeutic Potential of Extracellular Vesicles for Sepsis Treatment.Advanced therapeutics · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a clinical syndrome caused by a deregulated host response to an infection. Sepsis is the most frequent cause of death in hospitalized patients. Although knowledge of the pathogenesis of sepsis has increased substantially during the last decades, attempts to design effective and specific therapies targeting components of the derailed host response have failed. Therefore, there is a dramatic need for new and mechanistically alternative therapies to treat this syndrome. Based on their immunomodulatory properties, adult mesenchymal stem or stromal cells (MSCs) can be a novel therapeutic tool to treat sepsis. Indeed, MSCs reduce mortality in experimental models of sepsis by modulating the deregulated inflammatory response against bacteria through the regulation of multiple inflammatory networks, the reprogramming of macrophages and neutrophils towards a more anti-inflammatory phenotype and the release of anti-microbial peptides. This report will review the current knowledge on the effects of MSC treatment in preclinical experimental small animal models of sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.